A Phase II Study of Apatinib In Combination With Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Etoposide (Primary) ; Rivoceranib (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results (n=35) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 24 Jan 2018 Planned number of patients changed from 68 to 35.
- 24 Jan 2018 Planned End Date changed from 1 Dec 2020 to 1 Aug 2019.